CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. / Kobylecki, Camilla J; Jakobsen, Klaus D; Hansen, Thomas; Jakobsen, Ida V; Rasmussen, Henrik B; Werge, Thomas; Kobylecki, Camilla J; Jakobsen, Klaus D; Hansen, Thomas; Jakobsen, Ida V; Rasmussen, Henrik B; Werge, Thomas.
In: Neuropsychobiology, Vol. 59, No. 4, 2009, p. 222-6.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study
AU - Kobylecki, Camilla J
AU - Jakobsen, Klaus D
AU - Hansen, Thomas
AU - Jakobsen, Ida V
AU - Rasmussen, Henrik B
AU - Werge, Thomas
AU - Kobylecki, Camilla J
AU - Jakobsen, Klaus D
AU - Hansen, Thomas
AU - Jakobsen, Ida V
AU - Rasmussen, Henrik B
AU - Werge, Thomas
N1 - Keywords: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Retrospective Studies; Schizophrenia; Sequence Analysis, DNA
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: The aim of the present retrospective pilot study was to examine the clinical impact of the cytochrome P450 (CYP) enzyme CYP2D6 poor metabolizer (PM) genotype in patients taking antipsychotic medication. The impaired metabolic capacity of the PM genotype results in higher steady-state plasma concentrations at a given dose, thus increasing the risk of toxic effects from medication. METHODS: We identified 18 PM patients with a schizophrenia spectrum diagnosis from a clinical database covering all patients who have been analyzed in an ongoing standardized CYP2D6 screening program. Each PM patient was carefully matched on age, gender and diagnosis with an intermediate metabolizer (IM) and an extensive metabolizer (EM) from the same database to generate 18 triplets. Clinical data, primarily on side effects of treatment, were obtained from medical records by an experienced research and consultant psychiatrist, who was blinded to the results of the genotyping. RESULTS: We found that extrapyramidal syndrome or tardive dyskinesia (EPS/TD) was significantly more frequent among PM patients than among the matched IM and EM control subjects. This finding was further supported by the significantly higher prevalence of noncompliance among the same PM patients. Importantly, this association was not due to differences in the use of CYP2D6-dependent or EPS/TD-causing medication across the 3 matched patient groups. CONCLUSIONS: This leads us to conclude that genetically encoded differences in the rate of drug metabolism through CYP2D6 can predict antipsychotic side effects and prompts the question of whether genotyping early in the course of illness to facilitate adjustment of pharmacotherapy will improve treatment outcomes and reduce side effects.
AB - OBJECTIVE: The aim of the present retrospective pilot study was to examine the clinical impact of the cytochrome P450 (CYP) enzyme CYP2D6 poor metabolizer (PM) genotype in patients taking antipsychotic medication. The impaired metabolic capacity of the PM genotype results in higher steady-state plasma concentrations at a given dose, thus increasing the risk of toxic effects from medication. METHODS: We identified 18 PM patients with a schizophrenia spectrum diagnosis from a clinical database covering all patients who have been analyzed in an ongoing standardized CYP2D6 screening program. Each PM patient was carefully matched on age, gender and diagnosis with an intermediate metabolizer (IM) and an extensive metabolizer (EM) from the same database to generate 18 triplets. Clinical data, primarily on side effects of treatment, were obtained from medical records by an experienced research and consultant psychiatrist, who was blinded to the results of the genotyping. RESULTS: We found that extrapyramidal syndrome or tardive dyskinesia (EPS/TD) was significantly more frequent among PM patients than among the matched IM and EM control subjects. This finding was further supported by the significantly higher prevalence of noncompliance among the same PM patients. Importantly, this association was not due to differences in the use of CYP2D6-dependent or EPS/TD-causing medication across the 3 matched patient groups. CONCLUSIONS: This leads us to conclude that genetically encoded differences in the rate of drug metabolism through CYP2D6 can predict antipsychotic side effects and prompts the question of whether genotyping early in the course of illness to facilitate adjustment of pharmacotherapy will improve treatment outcomes and reduce side effects.
U2 - 10.1159/000223734
DO - 10.1159/000223734
M3 - Journal article
C2 - 19521114
VL - 59
SP - 222
EP - 226
JO - Neuropsychobiology
JF - Neuropsychobiology
SN - 0302-282X
IS - 4
ER -
ID: 21335829